25/03/2019 - Campus Can Ruti, Research

New financing from the Catalan NF2 Patients Association for Research into personalized medicine for Neurofibromatosis Type 2

Can Ruti has been awarded a research project by the Spanish Federation for Rare Diseases (FEDER) Foundation in their fourth call for research projects.  The winning project, led by Dr Ignacio Blanco and Dr Elisabeth Castellanos, from the Germans Trias I Pujol Hospital and Institute respectively, is one of five financed by the foundation this year. The research will focus personalized attention for Neurofibromatosis type 2 (NF2) patients to optimize evaluation of their quality of life and refine their classification during diagnosis.

28/02/2019 - Outreach, Research

Can Ruti shows it cares for rare diseases

The IGTP and the Germans Trias Hospital face the spotlight for rare diseases again.  This year our professionals are joining World Rare Disease Day on the last day of February to highlight these diseases and shine a light on the research activities in the field on campus.

13/02/2019 - Research

Induced pluripotent stem cells have been generated for the first time from tumor cells in order to study therapies for tumors developed in patients with hereditary diseases with predisposition to cancer

The study, by the Hereditary Cancer research group at the IGTP, focuses on characterizing induced pluripotent stem cells (iPSCs) from benign tumors, characteristic of Neurofibromatosis type 1 (NF1). The iPSCs are able to regenerate indefinitely and give rise to any other cell in the body so they represent an inexhaustible supply of cells to study tumors and new treatments.

20/12/2018 - Campus Can Ruti, Research

Phakomatosis experts get together at the IGTP

The professionals that make up the Reference Centre (CSUR) on Neurocutaneous Syndromes- Phakomatoses, have met up together at the IGTP. The aim of these regular meetings and mini-symposiums is to revise the work done in healthcare and research, including innovations, new approaches and the lines of research underway. The prescence of different professionals in the meeting provides a more global view of the work carried out by the whole group and a better reciprocal understanding of the healthcare and research aspects.

09/10/2018 - Research

New research projects in neurofibromatosis thanks to the support of the Neurofibromatosis Project Foundation

The Hereditary Cancer Research Group at the IGTP studies the genetic diseases that bring a high risk of developing cancer, one of which is neurofibromatosis (NF).  The group has just started two new projects to study neurofibromatosis types 1 and 2 thanks to the support of the Neurofibromatosis Project Foundation.

02/07/2018 - Research

The Hereditary Cancer Group at the IGTP provides another tool for the better management of patients diagnosed with NF1

In a study, published in Human Mutation led by Meritxell Carrió and Eduard Serra of the IGTP in collaboration with scientists from the ICO Hereditary Cancer Program, scientists studied 8 PNF tumours to find information to help doctors predict how tumours will develop.  They looked at the tissue characteristics of the tumors and then compared this to the genetic make-up of the cells within the tumour.

11/01/2018 - Research

Examination of skin plaques by a paediatric dermatologist has been confirmed as a reliable way to diagnose NF2 in children before symptoms appear

IGTP Scientists working with the Reference Centre for Phakomatoses in the Germans Trias i Pujol Hospital-ICO Badalona have confirmed what dermatologists on the team have long suspected.  Skin plaques in young children can be used to identify NF2 patients long before their symptoms appear.